Spyre Therapeutics Prices Public Offering at $62 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SYRE?
Source: Newsfilter
- Offering Size: Spyre Therapeutics announced a public offering of 6,500,000 shares at $62.00 per share, expected to raise approximately $403 million, demonstrating the company's strong fundraising capability in the biotechnology sector.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, indicating the company's credibility and attractiveness in the capital markets.
- Additional Purchase Option: The company granted underwriters a 30-day option to purchase an additional approximately $60.5 million of shares at the public offering price, which may further enhance the company's liquidity.
- Compliance and Transparency: Spyre has filed a registration statement with the SEC and received approval, ensuring compliance for the offering, which boosts investor confidence and promotes market interest in its future products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYRE
Wall Street analysts forecast SYRE stock price to fall
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 63.270
Low
40.00
Averages
56.67
High
70.00
Current: 63.270
Low
40.00
Averages
56.67
High
70.00
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Spyre Therapeutics Prices Public Offering at $62 per Share
- Offering Size: Spyre Therapeutics announced a public offering of 6,500,000 shares at $62.00 per share, expected to raise approximately $403 million, demonstrating the company's strong fundraising capability in the biotechnology sector.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, indicating the company's credibility and attractiveness in the capital markets.
- Additional Purchase Option: The company granted underwriters a 30-day option to purchase an additional approximately $60.5 million of shares at the public offering price, which may further enhance the company's liquidity.
- Compliance and Transparency: Spyre has filed a registration statement with the SEC and received approval, ensuring compliance for the offering, which boosts investor confidence and promotes market interest in its future products.
See More
Spyre Therapeutics Prices $403 Million Public Offering
- Offering Size: Spyre Therapeutics has announced a public offering of 6,500,000 shares at $62.00 per share, expected to raise approximately $403 million in gross proceeds, which will significantly bolster the company's funding for R&D and market expansion.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, reflecting strong market confidence in Spyre and potentially enhancing the company's reputation in the biotechnology sector.
- Additional Purchase Option: The company has granted underwriters a 30-day option to purchase an additional approximately $60.5 million of shares at the public offering price, which may further enhance liquidity and support future growth initiatives.
- Compliance and Transparency: Spyre has filed a registration statement with the SEC and published a preliminary prospectus on the SEC website, ensuring investors have access to transparent information, thereby increasing market trust.
See More
Spyre Therapeutics Launches $300 Million Public Offering
- Offering Size: Spyre Therapeutics has announced the commencement of a $300 million public offering of common stock, with an additional $45 million purchase option for underwriters within 30 days, aimed at funding its research projects.
- Underwriter Lineup: The offering is being managed by Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC, indicating strong market confidence and support for Spyre.
- Market Volatility Impact: Despite trading between $12.04 and $75 over the past year, Spyre's stock closed at $63.27 on Monday, up 23.36%, but fell 4.87% in after-hours trading to $60.19, reflecting cautious market sentiment regarding the offering.
- R&D Prospects: Spyre is focused on developing next-generation products for inflammatory bowel disease and other immune-mediated diseases, with a pipeline that includes various investigational antibodies, showcasing the company's long-term strategic potential in the biotech sector.
See More
Spyre Therapeutics Launches $300M Public Offering to Fund Drug Development
- Offering Size: Spyre Therapeutics has initiated a $300 million underwritten public offering, intending to raise funds through the direct sale of all shares to support its research and development in treatments for inflammatory bowel disease and other immune conditions.
- Underwriter Option: The company may allow underwriters to purchase an additional $45 million in shares within 30 days, providing flexibility that could enhance its capital-raising capabilities and financial stability.
- Use of Proceeds: The proceeds from the offering are expected to primarily fund the development of treatments for moderate-to-severe ulcerative colitis, indicating the company's strategic focus and potential for future growth in this therapeutic area.
- Market Sentiment: Spyre Therapeutics is rated as a “Strong Buy,” reflecting market confidence in its R&D progress, particularly in light of upcoming RA data and results from the SKYLINE trial.
See More
Spyre Therapeutics Launches $300 Million Public Offering
- Offering Size: Spyre Therapeutics has announced a public offering of $300 million, with an additional $45 million option for underwriters, reflecting the company's confidence in capital markets and its financing needs.
- Underwriter Lineup: The offering is being managed by Jefferies, Goldman Sachs, Evercore, and Guggenheim Securities, indicating the company's strong presence and appeal in the capital markets.
- Registration Statement: A registration statement was approved by the SEC on February 27, 2026, ensuring compliance for the offering and providing transparency for investors.
- Market Risk Advisory: The company highlights that the completion of the offering is subject to market and other conditions, with potential uncertainties such as economic slowdown and rising interest rates that could impact the actual size and terms of the offering.
See More
Spyre Therapeutics' Trial Data Boosts Stock by 23%
- Significant Stock Surge: Shares of Spyre Therapeutics Inc. (SYRE) soared 23% on Monday, marking its largest single-day gain since June 2023, driven by positive ulcerative colitis trial data that highlighted the drug's potential effectiveness.
- Trial Results Stand Out: The company reported that its SPY001 phase 2 trial met its primary endpoint with a statistically significant reduction in disease activity, and the drug was well tolerated, although six subjects experienced treatment-emergent adverse events, indicating a need for ongoing safety monitoring.
- Analyst Optimism: Analysts from TD Cowen and Leerink raised their price targets for Spyre, with TD Cowen increasing it to $80 and Leerink to $106 from $49, reflecting heightened confidence in SPY001's success in treating ulcerative colitis and Crohn's disease.
- Retail Investor Sentiment Shift: On Stocktwits, retail sentiment around SYRE stock shifted from 'neutral' to 'extremely bullish' within 24 hours, with message volume increasing from 'high' to 'extremely high', indicating strong investor confidence in Spyre's future performance.
See More
Spyre Therapeutics Prices Public Offering at $62 per Share
- Offering Size: Spyre Therapeutics announced a public offering of 6,500,000 shares at $62.00 per share, expected to raise approximately $403 million, demonstrating the company's strong fundraising capability in the biotechnology sector.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, indicating the company's credibility and attractiveness in the capital markets.
- Additional Purchase Option: The company granted underwriters a 30-day option to purchase an additional approximately $60.5 million of shares at the public offering price, which may further enhance the company's liquidity.
- Compliance and Transparency: Spyre has filed a registration statement with the SEC and received approval, ensuring compliance for the offering, which boosts investor confidence and promotes market interest in its future products.
See More
Spyre Therapeutics Prices $403 Million Public Offering
- Offering Size: Spyre Therapeutics has announced a public offering of 6,500,000 shares at $62.00 per share, expected to raise approximately $403 million in gross proceeds, which will significantly bolster the company's funding for R&D and market expansion.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, reflecting strong market confidence in Spyre and potentially enhancing the company's reputation in the biotechnology sector.
- Additional Purchase Option: The company has granted underwriters a 30-day option to purchase an additional approximately $60.5 million of shares at the public offering price, which may further enhance liquidity and support future growth initiatives.
- Compliance and Transparency: Spyre has filed a registration statement with the SEC and published a preliminary prospectus on the SEC website, ensuring investors have access to transparent information, thereby increasing market trust.
See More
Spyre Therapeutics Launches $300 Million Public Offering
- Offering Size: Spyre Therapeutics has announced the commencement of a $300 million public offering of common stock, with an additional $45 million purchase option for underwriters within 30 days, aimed at funding its research projects.
- Underwriter Lineup: The offering is being managed by Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC, indicating strong market confidence and support for Spyre.
- Market Volatility Impact: Despite trading between $12.04 and $75 over the past year, Spyre's stock closed at $63.27 on Monday, up 23.36%, but fell 4.87% in after-hours trading to $60.19, reflecting cautious market sentiment regarding the offering.
- R&D Prospects: Spyre is focused on developing next-generation products for inflammatory bowel disease and other immune-mediated diseases, with a pipeline that includes various investigational antibodies, showcasing the company's long-term strategic potential in the biotech sector.
See More
Spyre Therapeutics Launches $300M Public Offering to Fund Drug Development
- Offering Size: Spyre Therapeutics has initiated a $300 million underwritten public offering, intending to raise funds through the direct sale of all shares to support its research and development in treatments for inflammatory bowel disease and other immune conditions.
- Underwriter Option: The company may allow underwriters to purchase an additional $45 million in shares within 30 days, providing flexibility that could enhance its capital-raising capabilities and financial stability.
- Use of Proceeds: The proceeds from the offering are expected to primarily fund the development of treatments for moderate-to-severe ulcerative colitis, indicating the company's strategic focus and potential for future growth in this therapeutic area.
- Market Sentiment: Spyre Therapeutics is rated as a “Strong Buy,” reflecting market confidence in its R&D progress, particularly in light of upcoming RA data and results from the SKYLINE trial.
See More
Spyre Therapeutics Launches $300 Million Public Offering
- Offering Size: Spyre Therapeutics has announced a public offering of $300 million, with an additional $45 million option for underwriters, reflecting the company's confidence in capital markets and its financing needs.
- Underwriter Lineup: The offering is being managed by Jefferies, Goldman Sachs, Evercore, and Guggenheim Securities, indicating the company's strong presence and appeal in the capital markets.
- Registration Statement: A registration statement was approved by the SEC on February 27, 2026, ensuring compliance for the offering and providing transparency for investors.
- Market Risk Advisory: The company highlights that the completion of the offering is subject to market and other conditions, with potential uncertainties such as economic slowdown and rising interest rates that could impact the actual size and terms of the offering.
See More
Spyre Therapeutics' Trial Data Boosts Stock by 23%
- Significant Stock Surge: Shares of Spyre Therapeutics Inc. (SYRE) soared 23% on Monday, marking its largest single-day gain since June 2023, driven by positive ulcerative colitis trial data that highlighted the drug's potential effectiveness.
- Trial Results Stand Out: The company reported that its SPY001 phase 2 trial met its primary endpoint with a statistically significant reduction in disease activity, and the drug was well tolerated, although six subjects experienced treatment-emergent adverse events, indicating a need for ongoing safety monitoring.
- Analyst Optimism: Analysts from TD Cowen and Leerink raised their price targets for Spyre, with TD Cowen increasing it to $80 and Leerink to $106 from $49, reflecting heightened confidence in SPY001's success in treating ulcerative colitis and Crohn's disease.
- Retail Investor Sentiment Shift: On Stocktwits, retail sentiment around SYRE stock shifted from 'neutral' to 'extremely bullish' within 24 hours, with message volume increasing from 'high' to 'extremely high', indicating strong investor confidence in Spyre's future performance.
See More
